Fractyl Health, Inc. (GUTS)

NGM – Цена в реальном времени. Валюта: USD

0.73

-0.04 (-4.55%)

При закрытии: May 12, 2026, 4:00 PM EDT

0.79

+0.06 (7.63%)

До открытия: May 13, 2026, 9:18 AM EDT

13.05.2026

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

13.05.2026

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company's first-quarter 2026 earnings call.

12.05.2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1 Pivotal Cohort and late Q4 2026 timing for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance reaffirmed Clinical Trial Application authorization of RJVA-001 first-in-human study in the Netherlands for T2D; first-in-human dosing anticipated in second half of 2026 reiterated Cash runway guidance into early 2027, beyond anticipated Pivotal data readout reiterated Conference call today at 4:30 p.m. ET BURLINGTON, Mass.

11.05.2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes

05.05.2026

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m.

24.03.2026

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

17.03.2026

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

11.05.2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

26.02.2026

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data readout BURLINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced completion of participant randomization in its REMAIN-1 Pivotal Cohort, a double-blind, sham-controlled study evaluating Revita ® for weight maintenance following GLP-1 therapy discontinuation.

30.01.2026

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.

Fractyl Health, Inc. (GUTS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Видео

No Data

Пресс-релизы

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Видео

No Data

Пресс-релизы

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

Search stocks

Fractyl Health, Inc. (GUTS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Видео

No Data

Пресс-релизы

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Q1 Earnings Call Highlights

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Видео

No Data

Пресс-релизы

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS